XML 307 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations and Deficit - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Profit or loss [abstract]      
Revenue (Note 21) $ 41,427 $ 465,777 $ 552,748
Operating expenses      
Selling, marketing and administration (Note 20) 18,771,421 10,795,155 9,516,271
Research and development (Note 20) 11,334,641 10,077,930 10,746,743
Operating expenses 30,106,062 20,873,085 20,263,014
Operating loss before the following (30,064,635) (20,407,308) (19,710,266)
Loss on acquisition of 24.8% of SPX (Note 5) (6,852,687)
Interest expense (Note 8) (102,673) (70,182) (49,738)
Other income, including interest 947,956 234,990 188,320
Forgiveness of Covid-19 government support loans (Note 23) 7,298
Gain on contribution of intellectual property to joint venture (Note 5) 1,031,807 1,746,987
Share of loss in joint venture (Note 5) (1,031,807) (3,211,993)
Fair value adjustment to derivative warrant liability (Note 10 and 11(b)) (20,631,082) (24,865)
Net loss (56,695,823) (20,267,365) (21,036,690)
Deficit, beginning of year (214,291,025) (194,023,660) (172,986,970)
Net loss (56,695,823) (20,267,365) (21,036,690)
Deficit, end of year $ (270,986,848) $ (214,291,025) $ (194,023,660)
Basic net loss per share (Note 14) $ (0.94) $ (0.51) $ (0.57)
Diluted net loss per share (Note 14) $ (0.94) $ (0.51) $ (0.57)